An Essentialrole for LRP1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Reconfiguring Nature's Cholesterol Accepting Lipoproteins As
nanomaterials Review Reconfiguring Nature’s Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents , Skylar T. Chuang y z, Siobanth Cruz y and Vasanthy Narayanaswami * Department of Chemistry and Biochemistry, California State University, Long Beach, 1250 Bellflower Blvd, Long Beach, CA 90840, USA; [email protected] (S.T.C.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +1-562-985-4953; Fax: +1-562-985-8557 These authors contributed equally to this work. y Current address: Department of Chemistry and Chemical Biology, Rutgers University, 123 Bevier Road, z Piscataway, NJ 08854, USA. Received: 2 March 2020; Accepted: 29 April 2020; Published: 8 May 2020 Abstract: Apolipoproteins are critical structural and functional components of lipoproteins, which are large supramolecular assemblies composed predominantly of lipids and proteins, and other biomolecules such as nucleic acids. A signature feature of apolipoproteins is the preponderance of amphipathic α-helical motifs that dictate their ability to make extensive non-covalent inter- or intra-molecular helix–helix interactions in lipid-free states or helix–lipid interactions with hydrophobic biomolecules in lipid-associated states. This review focuses on the latter ability of apolipoproteins, which has been capitalized on to reconstitute synthetic nanoscale binary/ternary lipoprotein complexes composed of apolipoproteins/peptides and lipids that mimic native high-density lipoproteins (HDLs) with the goal to transport drugs. It traces the historical development of our understanding of these nanostructures and how the cholesterol accepting property of HDL has been reconfigured to develop them as drug-loading platforms. The review provides the structural perspective of these platforms with different types of apolipoproteins and an overview of their synthesis. -
Receptor-Arrestin Interactions: the GPCR Perspective
biomolecules Review Receptor-Arrestin Interactions: The GPCR Perspective Mohammad Seyedabadi 1,2 , Mehdi Gharghabi 3, Eugenia V. Gurevich 4 and Vsevolod V. Gurevich 4,* 1 Department of Toxicology & Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari 48471-93698, Iran; [email protected] 2 Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari 48167-75952, Iran 3 Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; [email protected] 4 Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-615-322-7070; Fax: +1-615-343-6532 Abstract: Arrestins are a small family of four proteins in most vertebrates that bind hundreds of different G protein-coupled receptors (GPCRs). Arrestin binding to a GPCR has at least three functions: precluding further receptor coupling to G proteins, facilitating receptor internalization, and initiating distinct arrestin-mediated signaling. The molecular mechanism of arrestin–GPCR interactions has been extensively studied and discussed from the “arrestin perspective”, focusing on the roles of arrestin elements in receptor binding. Here, we discuss this phenomenon from the “receptor perspective”, focusing on the receptor elements involved in arrestin binding and empha- sizing existing gaps in our knowledge that need to be filled. It is vitally important to understand the role of receptor elements in arrestin activation and how the interaction of each of these elements with arrestin contributes to the latter’s transition to the high-affinity binding state. A more precise knowledge of the molecular mechanisms of arrestin activation is needed to enable the construction of arrestin mutants with desired functional characteristics. -
When 7 Transmembrane Receptors Are Not G Protein–Coupled Receptors
When 7 transmembrane receptors are not G protein–coupled receptors Keshava Rajagopal, … , Robert J. Lefkowitz, Howard A. Rockman J Clin Invest. 2005;115(11):2971-2974. https://doi.org/10.1172/JCI26950. Commentary Classically, 7 transmembrane receptors transduce extracellular signals by coupling to heterotrimeric G proteins, although recent in vitro studies have clearly demonstrated that they can also signal via G protein–independent mechanisms. However, the physiologic consequences of this unconventional signaling, particularly in vivo, have not been explored. In this issue of the JCI, Zhai et al. demonstrate in vivo effects of G protein–independent signaling by the angiotensin II type 1 receptor (AT1R). In studies of the mouse heart, they compare the physiologic and biochemical consequences of transgenic cardiac-specific overexpression of a mutant AT1R incapable of G protein coupling with those of a wild-type receptor. Their results not only provide the first glimpse of the physiologic effects of this newly appreciated mode of signaling but also provide important and previously unappreciated clues as to the underlying molecular mechanisms. Find the latest version: https://jci.me/26950/pdf commentaries gene, spastin, regulates microtubule stability to 16. Wittmann, C.W., et al. 2001. Tauopathy in Dro- 21. Chan, Y.B., et al. 2003. Neuromuscular defects in modulate synaptic structure and function. Curr. sophila: neurodegeneration without neurofibril- a Drosophila survival motor neuron gene mutant. Biol. 14:1135–1147. lary tangles. Science. 293:711–714. Hum. Mol. Genet. 12:1367–1376. 12. Sherwood, N.T., Sun, Q., Xue, M., Zhang, B., and 17. Shapiro, W.R., and Young, D.F. -
Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
International Journal of Molecular Sciences Review Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases Valentina Giudice 1,2,* , Francesca Mensitieri 1, Viviana Izzo 1,2 , Amelia Filippelli 1,2 and Carmine Selleri 1 1 Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi, 84081 Salerno, Italy; [email protected] (F.M.); [email protected] (V.I.); afi[email protected] (A.F.); [email protected] (C.S.) 2 Unit of Clinical Pharmacology, University Hospital “San Giovanni di Dio e Ruggi D’Aragona”, 84131 Salerno, Italy * Correspondence: [email protected]; Tel.: +39-(0)-89965116 Received: 30 March 2020; Accepted: 2 May 2020; Published: 4 May 2020 Abstract: Aptamers or chemical antibodies are single-stranded DNA or RNA oligonucleotides that bind proteins and small molecules with high affinity and specificity by recognizing tertiary or quaternary structures as antibodies. Aptamers can be easily produced in vitro through a process known as systemic evolution of ligands by exponential enrichment (SELEX) or a cell-based SELEX procedure. Aptamers and modified aptamers, such as slow, off-rate, modified aptamers (SOMAmers), can bind to target molecules with less polar and more hydrophobic interactions showing slower dissociation rates, higher stability, and resistance to nuclease degradation. Aptamers and SOMAmers are largely employed for multiplex high-throughput proteomics analysis with high reproducibility and reliability, for tumor cell detection by flow cytometry or microscopy for research and clinical purposes. In addition, aptamers are increasingly used for novel drug delivery systems specifically targeting tumor cells, and as new anticancer molecules. In this review, we summarize current preclinical and clinical applications of aptamers in malignant and non-malignant hematological diseases. -
G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types. -
1 Presenilin-Based Genetic Screens in Drosophila Melanogaster Identify
Genetics: Published Articles Ahead of Print, published on January 16, 2006 as 10.1534/genetics.104.035170 Presenilin-based genetic screens in Drosophila melanogaster identify novel Notch pathway modifiers Matt B. Mahoney*1, Annette L. Parks*2, David A. Ruddy*3, Stanley Y. K. Tiong*, Hanife Esengil4, Alexander C. Phan5, Panos Philandrinos6, Christopher G. Winter7, Kari Huppert8, William W. Fisher9, Lynn L’Archeveque10, Felipa A. Mapa11, Wendy Woo, Michael C. Ellis12, Daniel Curtis11 Exelixis, Inc., South San Francisco, California, 94083 Present addresses: 1Department of Discovery, EnVivo Pharmaceuticals, Watertown, Massachusetts, 02472 2Biology Department, Boston College, Chestnut Hill, Massachusetts, 02467 3Oncology Targets and Biomarkers, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, 02139 4Department of Molecular Pharmacology, Stanford University, Stanford, California, 94305 5Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205 6ITHAKA Academic Cultural Program in Greece, San Francisco, California, 94102 7Merck Research Laboratories, Boston, Massachusetts, 02115 8Donald Danforth Plant Science Center, St. Louis, Missouri, 63132 1 9Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, 94720 10Biocompare, Inc., South San Francisco, California, 94080 11Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, 02139 12Renovis, Inc., South San Francisco, California, 94080 -
Sleeping Beauty Transposon Mutagenesis Identifies Genes That
Sleeping Beauty transposon mutagenesis identifies PNAS PLUS genes that cooperate with mutant Smad4 in gastric cancer development Haruna Takedaa,b, Alistair G. Rustc,d, Jerrold M. Warda, Christopher Chin Kuan Yewa, Nancy A. Jenkinsa,e, and Neal G. Copelanda,e,1 aDivision of Genomics and Genetics, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore 138673; bDepartment of Pathology, School of Medicine, Kanazawa Medical University, Ishikawa 920-0293, Japan; cExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10 1HH, United Kingdom; dTumour Profiling Unit, The Institute of Cancer Research, Chester Beatty Laboratories, London SW3 6JB, United Kingdom; and eCancer Research Program, Houston Methodist Research Institute, Houston, TX 77030 Contributed by Neal G. Copeland, February 27, 2016 (sent for review October 15, 2015; reviewed by Yoshiaki Ito and David A. Largaespada) Mutations in SMAD4 predispose to the development of gastroin- animal models that mimic human GC, researchers have infected testinal cancer, which is the third leading cause of cancer-related mice with H. pylori and then, treated them with carcinogens. They deaths. To identify genes driving gastric cancer (GC) development, have also used genetic engineering to develop a variety of trans- we performed a Sleeping Beauty (SB) transposon mutagenesis genic and KO mouse models of GC (10). Smad4 KO mice are one + − screen in the stomach of Smad4 / mutant mice. This screen iden- GC model that has been of particular interest to us (11, 12). tified 59 candidate GC trunk drivers and a much larger number of Heterozygous Smad4 KO mice develop polyps in the pyloric re- candidate GC progression genes. -
LRP1B Mutations Are Associated with Favorable Outcomes to Immune Checkpoint Inhibitors Across Multiple Cancer Types
Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001792 on 2 March 2021. Downloaded from LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types 1 2 3 4 Landon C Brown , Matthew D Tucker , Ramy Sedhom, Eric B Schwartz, 5 1 1 1 Jason Zhu, Chester Kao, Matthew K Labriola , Rajan T Gupta, 1 6 1 1 1 Daniele Marin, Yuan Wu, Santosh Gupta, Tian Zhang , Michael R Harrison, Daniel J George,1 Ajjai Alva,4 Emmanuel S Antonarakis,3 Andrew J Armstrong1 To cite: Brown LC, Tucker MD, ABSTRACT lung cancer (NSCLC) and renal cell carci- Sedhom R, et al. LRP1B Background Low- density lipoprotein receptor- related noma.1–3 However, not all patients respond mutations are associated with protein 1b (encoded by LRP1B) is a putative tumor favorable outcomes to immune to treatment with ICIs. The use of predictive suppressor, and preliminary evidence suggests LRP1B- checkpoint inhibitors across biomarkers for response has been explored mutated cancers may have improved outcomes with multiple cancer types. Journal in many tumor types with varying degrees immune checkpoint inhibitors (ICI). for ImmunoTherapy of Cancer of success. Programmed-death ligand-1 (PD- Methods We conducted a multicenter, retrospective pan- 2021;9:e001792. doi:10.1136/ L1) expression,1 microsatellite instability jitc-2020-001792 cancer analysis of patients with LRP1B alterations treated 4 with ICI at Duke University, Johns Hopkins University (JHU) (MSI)/mismatch repair deficiency and 5 6 These data were presented at and University of Michigan (UM). The primary objective tumor mutational burden (TMB) are the the ASCO annual meeting 2020, was to assess the association between overall response only FDA- approved predictive biomarkers for Abstract # 3007. -
The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota. -
Identification of LRP1B-Interacting Proteins and Inhibition of Protein
FEBS Letters 583 (2009) 43–48 journal homepage: www.FEBSLetters.org Identification of LRP1B-interacting proteins and inhibition of protein kinase Ca-phosphorylation of LRP1B by association with PICK1 Tomoko Shiroshima, Chio Oka, Masashi Kawaichi * Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan article info abstract Article history: Recent studies show LDL receptor-related protein 1B, LRP1B as a transducer of extracellular signals. Received 17 October 2008 Here, we identify six interacting partners of the LRP1B cytoplasmic region by yeast two-hybrid Revised 9 November 2008 screen and confirmed their in vivo binding by immunoprecipitation. One of the partners, PICK1 rec- Accepted 18 November 2008 ognizes the C-terminus of LRP1B and LRP1. The cytoplasmic domains of LRP1B are phosphorylated Available online 9 December 2008 by PKCa about 100 times more efficiently than LRP1. Binding of PICK1 inhibits phosphorylation of Edited by Gianni Cesareni LRP1B, but does not affect LRP1 phosphorylation. This study presents the possibility that LRP1B participates in signal transduction which PICK1 may regulate by inhibiting PKC phosphorylation of LRP1B. Keywords: a LDL receptor family LRP1B Structured summary: LRP1 MINT-6801075: Lrp1b (uniprotkb:Q9JI18) physically interacts (MI:0218) with SNTG2 (uniprotkb:Q925E0) PICK1 by two hybrid (MI:0018) JIP MINT-6801030, MINT-6801468: Lrp1b (uniprotkb:Q9JI18) physically interacts (MI:0218) with Pick1 (uni- PDZ domain protkb:Q80VC8) by two -
Membrane for Actin Bundle Formation P38 MAPK Signalosome at The
Platelet-Activating Factor-Induced Clathrin-Mediated Endocytosis Requires β -Arrestin-1 Recruitment and Activation of the p38 MAPK Signalosome at the Plasma This information is current as Membrane for Actin Bundle Formation of September 24, 2021. Nathan J. D. McLaughlin, Anirban Banerjee, Marguerite R. Kelher, Fabia Gamboni-Robertson, Christine Hamiel, Forest R. Sheppard, Ernest E. Moore and Christopher C. Silliman J Immunol 2006; 176:7039-7050; ; Downloaded from doi: 10.4049/jimmunol.176.11.7039 http://www.jimmunol.org/content/176/11/7039 http://www.jimmunol.org/ References This article cites 49 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/176/11/7039.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Platelet-Activating Factor-Induced Clathrin-Mediated Endocytosis Requires -Arrestin-1 Recruitment and Activation of the p38 MAPK Signalosome at the Plasma Membrane for Actin Bundle Formation1 Nathan J. -
Analysis of the Dystrophin Interactome
Analysis of the dystrophin interactome Dissertation In fulfillment of the requirements for the degree “Doctor rerum naturalium (Dr. rer. nat.)” integrated in the International Graduate School for Myology MyoGrad in the Department for Biology, Chemistry and Pharmacy at the Freie Universität Berlin in Cotutelle Agreement with the Ecole Doctorale 515 “Complexité du Vivant” at the Université Pierre et Marie Curie Paris Submitted by Matthew Thorley born in Scunthorpe, United Kingdom Berlin, 2016 Supervisor: Simone Spuler Second examiner: Sigmar Stricker Date of defense: 7th December 2016 Dedicated to My mother, Joy Thorley My father, David Thorley My sister, Alexandra Thorley My fiancée, Vera Sakhno-Cortesi Acknowledgements First and foremost, I would like to thank my supervisors William Duddy and Stephanie Duguez who gave me this research opportunity. Through their combined knowledge of computational and practical expertise within the field and constant availability for any and all assistance I required, have made the research possible. Their overarching support, approachability and upbeat nature throughout, while granting me freedom have made this year project very enjoyable. The additional guidance and supported offered by Matthias Selbach and his team whenever required along with a constant welcoming invitation within their lab has been greatly appreciated. I thank MyoGrad for the collaboration established between UPMC and Freie University, creating the collaboration within this research project possible, and offering research experience in both the Institute of Myology in Paris and the Max Delbruck Centre in Berlin. Vital to this process have been Gisele Bonne, Heike Pascal, Lidia Dolle and Susanne Wissler who have aided in the often complex processes that I am still not sure I fully understand.